Stock Analysis·← Pickers

ACOG

Alpha Cognition Inc

Alpha Cognition Inc (ACOG) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 70.4 (overbought), with 3/3 trend checks passing.

Price
$8.30
2026-07-16
Trend score
3/3
Uptrend
RSI (14)
70.4
Overbought
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

ACOG with MA50 and MA200

9.998.627.255.874.5007/3110/2401/2204/1707/15
ACOG2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$6.55+26.64% vs price
MA200
$6.20+33.81% vs price
RSI (14)
70.4Overbought zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for ACOG

Alpha Cognition Inc (ACOG) is still trading in a constructive trend overall. The latest available price is $8.30, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 26.6% and above the 200-day moving average by 33.8%.

Momentum and stretch context

ACOG currently has an RSI reading of 70.4, which suggests stronger momentum and a more stretched short-term backdrop. Trend traders may still find that attractive, while more patient traders may prefer to wait and see whether the stock cools off first.

What traders may watch next

For traders reviewing ACOG next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About Alpha Cognition Inc

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Sector
Financial Services
Industry
Financial - Conglomerates
CEO
Michael E. McFadden
Employees
71
Market cap
$128.9M
Beta
2.33
52-week range
$4.50 – $10.59
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
12 Nov 2024
ISIN
CA02074J5017
CUSIP
02074J501
Company profile data from Financial Modeling Prep. ACOG listed on NASDAQ.
Share dilution

ACOG shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Oct 2018Mar 2026
Shares outstanding (latest)
21.8M
Since Oct 2018
+204104.4%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. ACOG28 data points from Oct 2018 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about ACOG

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.